Table 3 Outcomes: chemotherapy received, dose reduction and delays.
Variable | All patients, N = 142 | Adjuvant setting, N = 77 | Palliative setting, N = 44 | ||||||
|---|---|---|---|---|---|---|---|---|---|
I N = 71, n (%) | C N = 71, n (%) | P | I N = 40, n (%) | C N = 37, n (%) | P | I N = 22, n (%) | C N = 22, n (%) | P | |
Completed planned treatment (primary endpoint) initial dose in all planned cycles | 32 (45) | 20 (28) | 0.0366 | 20 (50) | 8 (22) | 0.0097 | 7 (32) | 8 (36) | 0.751 |
Reduced start dose | 44 (62) | 41 (58) | 0.732 | 23 (58) | 16 (43) | 0.211 | 15 (68) | 19 (86) | 0.150 |
Reduction of chemotherapy during treatment | 20 (28) | 32 (45) | 0.037 | 10 (25) | 21 (57) | 0.005 | 8 (36) | 7 (32) | 0.750 |
Treatment delay | 25 (35) | 24 (34) | 0.860 | 8 (20) | 15 (41) | 0.049 | 13 (59) | 6 (27) | 0.033 |
Received initial dose in all given cycles | 46 (65) | 30 (42) | 0.007 | 25 (63) | 11 (30) | 0.004 | 14 (64) | 12 (59) | 0.540 |
Received all planned cycles | 41 (58) | 39 (55) | 0.735 | 26 (65) | 21 (57) | 0.459 | 10 (45) | 11 (50) | 0.763 |
Median (range) | P | Median (range) | P | Median (range) | P | ||||
Dose intensity: capecitabine/5-FU (%) | 84 (35–117) | 89 (11–117) | 0.724 | 89 (67–117) | 95 (47–117) | 0.662 | 93 (35–112) | 75 (11–100) | 0.343 |
Dose intensity: oxaliplatin (%) | 75 (22–169) | 87 (31–130) | 0.134 | 80 (22–169) | 87 (31–92) | 0.304 | 78 (49–103) | 76 (76–76) | 1.000 |
Dose intensity: irinotecan (%) | 65 (27–116) | 66 (4–110) | 0.883 | – | – | – | 67 (27–116) | 63 (4–104) | 0.240 |
% of planned cycles received capecitabine/5-FU | 100 (8–100) | 100 (8–100) | NA | 100 (8–100) | 100 (8–100) | NA | 89 (13–100) | 92 (13–100) | 0.763 |
% of planned cycles received oxaliplatin | 58 (8–100) | 63 (8–100) | 0.825 | 50 (8–100) | 50 (8–100) | 0.888 | 89 (25–100) | 100 (100–100) | 1.000 |
% of planned cycles received irinotecan | 93 (60–100) | 96 (25–100) | 0.751 | – | – | – | 91 (60–100) | 90 (25–100) | 1.000 |
Duration of chemotherapy (weeks) | 22.1 (0.3–43) | 20.1 (0.1–53) | 0.905 | 22.6 (0.3–27) | 22.4 (0.3–29) | 0.855 | 17.2 (0.3–43) | 21.6 (0.1–52) | 0.675 |
